TAO2 Inhibitors
TAO2 inhibitors, also known as TAO kinase inhibitors, belong to a specialized class of chemical compounds that have garnered significant attention in the realm of molecular biology and cell signaling research. TAO2, or TAO kinase 2, is a member of the sterile 20-like (STE20) kinase family, which plays a pivotal role in various cellular processes, particularly in the regulation of the mitogen-activated protein kinase (MAPK) signaling pathway. These inhibitors are designed to selectively target and inhibit the activity of TAO2 kinases, thereby modulating downstream signaling events.
The TAO2 inhibitors typically possess a specific structural configuration that enables them to interact with the catalytic domain of the TAO2 kinase. This interaction disrupts the kinase's ability to phosphorylate its substrates, leading to downstream effects on the MAPK signaling cascade. Consequently, TAO2 inhibitors have become valuable tools for researchers seeking to decipher the intricacies of cell signaling pathways and their role in diverse physiological and pathological processes. Understanding the molecular mechanisms influenced by TAO2 inhibitors can provide insights into cell proliferation, differentiation, apoptosis, and responses to external stimuli, all of which are crucial for advancing our knowledge of fundamental biology.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190 is a potent inhibitor of p38 MAP kinase, which is involved in the same pathway as TAO2. By inhibiting p38 MAPK activity, SB202190 can prevent TAO2-mediated signaling events that depend on p38 MAPK, leading to reduced TAO2 activity. | ||||||
LY-333,531 Hydrochloride | 169939-93-9 | sc-364215 sc-364215A | 1 mg 5 mg | $94.00 $287.00 | 6 | |
LY333531 is a selective inhibitor of protein kinase C beta (PKCβ). Since PKCβ can phosphorylate different substrates in the MAPK pathway, its inhibition may affect the signaling context of TAO2, potentially decreasing TAO2 activity due to altered pathway dynamics. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $224.00 $386.00 | 5 | |
BIX 02189 is a selective inhibitor of MEK5, which is involved in the MAPK/ERK5 pathway. Given that TAO2 can phosphorylate MEKs, inhibiting MEK5 could indirectly reduce the activation of TAO2 by affecting the downstream ERK5 signaling. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is an inhibitor of both MEK1 and MEK2, which are upstream regulators of ERK1/2 in the MAPK pathway. Inhibition of MEKs can lead to decreased ERK activity, potentially causing a reduction in TAO2 activity since TAO2 can act upstream of MEKs. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several receptor tyrosine kinases and downstream signaling components. By inhibiting RAF kinases, sorafenib can indirectly affect the MAPK pathway and consequently TAO2 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As mentioned previously, SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK pathway. While it was listed as an activator earlier due to its complex role in the pathway, as an inhibitor of JNK, it could also diminish TAO2 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is an inhibitor of the Rho-associated protein kinase (ROCK). Though ROCK is not directly related to TAO2, the Rho/ROCK pathway can intersect with MAPK signaling, and thus, inhibiting ROCK can potentially reduce TAO2 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, this compound can alter AKT signaling and subsequently impact the MAPK pathway, which may lead to a reduction in TAO2 kinase activity. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö6976 is a classic protein kinase C (PKC) inhibitor. Since PKC isoforms can phosphorylate multiple targets within the MAPK pathway, inhibiting PKC could indirectly downregulate TAO2 activity. | ||||||
Apocynin | 498-02-2 | sc-203321 sc-203321A sc-203321B sc-203321C | 1 g 10 g 100 g 500 g | $27.00 $68.00 $116.00 $360.00 | 74 | |
Apocynin inhibits the assembly of NADPH-oxidase, which can lead to reduced reactive oxygen species (ROS) production. ROS can modulate MAPK pathway activity, and thus, inhibiting ROS production could indirectly diminish the activation of TAO2. | ||||||